Recruiting

Omega-3 Supplements

Sponsor:

Nordic Naturals

Code:

NCT07900425

Conditions

Omega 3 Index

Nutrient Status

Healthy Adult Participants

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Omega-3 Softgel

Ultimate Omega Softgel

Ultimate Omega 2X Softgel

Ultimate Omega One Daily Softgel

Ultimate Omega Plant-Based Softgel

Study Details

Brief summary:

Heart disease is the leading cause of death worldwide. The Omega-3 Index (O3I) is a blood test that measures the amount of the omega-3 fats EPA and DHA in red blood cells. Research suggests that people with an O3I above 8% have a lower risk of dying from coronary heart disease than people with an O3I below 4%.

Eating fatty fish two or more times per week may help improve omega-3 status, but many people do not eat enough fish because of taste preferences or concerns about contaminants. Omega-3 supplements, such as fish oil and algae oil, can provide EPA and DHA directly and may help raise the Omega-3 Index. Research suggests that algae oil can be as effective as fish oil for increasing EPA and DHA levels.

This study will evaluate whether different fish-oil and algae-oil products-including softgels, liquids, and gummies-improve omega-3 status in healthy adults who eat little fatty fish. Participants will be asked to keep their usual diet, activity, medications, supplements, and lifestyle habits as consistent as possible during the study.

Conditions

Omega 3 Index

Nutrient Status

Healthy Adult Participants

Study ID

NCT07900425

Start date

Oct 26, 2026

Status verified date

Oct, 2026

Completion date

Dec 1, 2027

Anticipated

Primary completion date

Oct 26, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria

1. Males and females 18 years and older
2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,

Individuals of child-bearing potential must self-report that they are not pregnant and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

  • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
  • Double-barrier method
  • Intrauterine devices
  • Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
  • Vasectomy of partner at least 6 months prior to screening
  • Abstinence and agrees to use contraception if planning on becoming sexually active during the study 3. Normal diet includes low fatty fish intake (≤4 servings per month) 4. Agrees to avoid consuming foods and beverages fortified with omega-3 fatty acids for the study duration 5. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study 6. Provided voluntary, written, informed consent to participate in the study 7. Willing and able to consume study product and complete all questionnaires, diaries, and assessments required for participation 8. Healthy as determined by medical history and no unstable diagnosed medical conditions 7.2 Exclusion Criteria

1. Individuals who self-report as being pregnant, breast feeding, or planning to become pregnant during the study
2. Self-reported allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational product or placebo ingredients
3. Self-reported allergy to marine foods and/or by-products (e.g, fish, shellfish, or seafood)
4. Self-reported current use of omega-3 supplements (see Section 7.3.2)
5. Self-reported ongoing and unstable diseases/conditions in the past six months, including:

1. Gastrointestinal diseases
2. Hypertension
3. Type I or type II diabetes
4. Cardiovascular disease
5. Kidney and/or liver diseases
6. Thyroid condition
7. Autoimmune disease or immune compromised
6. Self-reported confirmation of any significant psychological condition/disorders
7. Self-reported major surgery in the past 3 months or individuals who have planned surgery during the course of the study
8. Self-reported cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
9. Self-reported confirmation of blood/bleeding disorders
10. Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis
11. Self-reported alcohol intake average of >2 standard drinks per day
12. Self-reported alcohol or drug abuse within the last 12 months that has required treatment
13. Self-reported use of cannabinoid products of >2 times per week
14. Self-reported current use of prescribed and/or OTC medications/supplements that may impact the efficacy and/or safety of the investigational product (Sections 7.3.1 and 7.3.2)
15. Participation in other clinical research studies 30 days prior to randomization
16. Individuals who are unable to give informed consent
17. Any other condition or lifestyle factor that may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant 7.3 Concomitant Medications Participants who are taking any prescribed medications that are considered not to affect the study outcomes must agree to maintain their current dosing regimen during the study unless otherwise recommended by their general practitioner/nurse practitioner.

7.3.1 Prescribed Medications Not applicable. 7.3.2 Over-the-counter Medications, Supplements, and Food/Drinks Participants who are currently consuming the following OTC medications, supplement and food/drinks will not be allowed to participate..

1\. Omega-3 supplements

Study Design

Enrollment

600 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

placebo comparator: Placebo Softgel

Placebo softgel

placebo comparator: Placebo Liquid

Placebo liquid

experimental: Ultimate Omega Softgel

Ultimate Omega Softgel

experimental: Omega-3 Liquid

Omega-3 Liquid

experimental: Omega-3 Softgel

Omega-3 Softgel

experimental: Ultimate Omega Mini Softgel

Ultimate Omega Mini Softgel

experimental: Ultimate Omega One Daily Softgel

Ultimate Omega One Daily Softgel

experimental: Ultimate Omega Plant-Based Softgel

Ultimate Omega Plant-Based Softgel

experimental: RO SE Softgel

RO SE Softgel

experimental: Ultimate Omega 2X Softgel

Ultimate Omega 2X Softgel

experimental: Ultimate Omega Liquid

Ultimate Omega Liquid

experimental: Ultimate Omega Gummy Chew

Ultimate Omega Gummy Chew

Interventions

Omega-3 Softgel

Omega-3 Softgel

Ultimate Omega Softgel

Ultimate Omega Softgel

Ultimate Omega 2X Softgel

Ultimate Omega 2X Softgel

Ultimate Omega One Daily Softgel

Ultimate Omega One Daily Softgel

Ultimate Omega Plant-Based Softgel

Ultimate Omega Plant-Based Softgel

Ultimate Omega Liquid

Ultimate Omega Liquid

Omega-3 Liquid

Omega-3 Liquid

RO SE

RO SE

placebo softgel

placebo softgel

Placebo Liquid

Placebo Liquid

Ultimate Omega Mini

Ultimate Omega Mini

Ultimate Omega Gummy Chew

Ultimate Omega Gummy Chew

Primary outcome measure

  • Omega-3 Index [ Time Frame: 3 months ]

Central Contacts and Locations

Locations

KGK Science Inc

Recruiting

London, Ontario, Canada, N6B 3L1

Contacts

Principal Investigator:

David Crowley, MD

More Information

Sponsor

Nordic Naturals

Last update posted

Oct 28, 2026

Last verified

Oct, 2026

Keywords

  • Omega-3
  • Omega-3 index
  • Supplements
  • Fish oil
  • Algae oil
  • Healthy adults

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-29. This information was provided to ClinicalTrials.gov by Nordic Naturals on 2026-10-28. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.